Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRE-ex trial of fecal microbiota transfer for VRE eradication in immunocompromised adults
2026-525632-41-00Phase 2Authorised
- Sponsor
- Fraunhofer Institute for Translational Medicine and Pharmacology
- Start
- Oct 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of INTESTIFIX 001 in vancomycin-resistant enterococcal colonization (3 arms), sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology. Primary endpoint: VRE decolonization rate on day 30 after two-dose FMT versus placebo. Planned start Oct 2026; status: authorised.
02
Drugs
INTESTIFIX 001
03
Conditions
vancomycin-resistant enterococcal colonization
Beyond the preview
Go deeper on 2026-525632-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525632-41-00.